Etyang, Anthony O; Lucinde, Ruth; Karanja, Henry; Kalu, Catherine; Mugo, Daisy; Nyagwange, James; Gitonga, John; Tuju, James; Wanjiku, Perpetual; Karani, Angela; +40 more... Mutua, Shadrack; Maroko, Hosea; Nzomo, Eddy; Maitha, Eric; Kamuri, Evanson; Kaugiria, Thuranira; Weru, Justus; Ochola, Lucy B; Kilimo, Nelson; Charo, Sande; Emukule, Namdala; Moracha, Wycliffe; Mukabi, David; Okuku, Rosemary; Ogutu, Monicah; Angujo, Barrack; Otiende, Mark; Bottomley, Christian; Otieno, Edward; Ndwiga, Leonard; Nyaguara, Amek; Voller, Shirine; Agoti, Charles N; Nokes, David James; Ochola-Oyier, Lynette Isabella; Aman, Rashid; Amoth, Patrick; Mwangangi, Mercy; Kasera, Kadondi; Ng'ang'a, Wangari; Adetifa, Ifedayo MO; Wangeci Kagucia, E; Gallagher, Katherine; Uyoga, Sophie; Tsofa, Benjamin; Barasa, Edwine; Bejon, Philip; Scott, J Anthony G; Agweyu, Ambrose; Warimwe, George M; (2021) Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 74 (2). pp. 288-293. ISSN 1058-4838 DOI: https://doi.org/10.1093/cid/ciab346
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Abstract
BACKGROUND: Few studies have assessed the seroprevalence of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among healthcare workers (HCWs) in Africa. We report findings from a survey among HCWs in 3 counties in Kenya. METHODS: We recruited 684 HCWs from Kilifi (rural), Busia (rural), and Nairobi (urban) counties. The serosurvey was conducted between 30 July and 4 December 2020. We tested for immunoglobulin G antibodies to SARS-CoV-2 spike protein, using enzyme-linked immunosorbent assay. Assay sensitivity and specificity were 92.7 (95% CI, 87.9-96.1) and 99.0% (95% CI, 98.1-99.5), respectively. We adjusted prevalence estimates, using bayesian modeling to account for assay performance. RESULTS: The crude overall seroprevalence was 19.7% (135 of 684). After adjustment for assay performance, seroprevalence was 20.8% (95% credible interval, 17.5%-24.4%). Seroprevalence varied significantly (P < .001) by site: 43.8% (95% credible interval, 35.8%-52.2%) in Nairobi, 12.6% (8.8%-17.1%) in Busia and 11.5% (7.2%-17.6%) in Kilifi. In a multivariable model controlling for age, sex, and site, professional cadre was not associated with differences in seroprevalence. CONCLUSION: These initial data demonstrate a high seroprevalence of antibodies to SARS-CoV-2 among HCWs in Kenya. There was significant variation in seroprevalence by region, but not by cadre.
Item Type | Article |
---|---|
Faculty and Department |
Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology & International Health (2023-) Faculty of Epidemiology and Population Health > Dept of Medical Statistics |
Research Centre |
Covid-19 Research Vaccine Centre Centre for Epidemic Preparedness and Response |
PubMed ID | 33893491 |
Elements ID | 159712 |
Download
Filename: Etyang_etal_2021_Seroprevalence-of-antibodies-to-severe.pdf
Licence: Creative Commons: Attribution 3.0
Download